Thomas Powles, MD, PhD, on Adding Radiation to Immunotherapy for RCC: Improving Systemic Control Through Local Therapy
2020 Genitourinary Cancers SymposiumThomas Powles, MD, PhD, of Queen Mary University of London, summarizes two papers on metastatic renal cell carcinoma for which he was the discussant: nivolumab in combination with stereotactic body radiotherapy in pretreated patients, and combining dual immune checkpoint inhibition with stereotactic radiation (Abstracts 613 & 614).
Related Videos
Nizar M. Tannir, MD, on Nivolumab/Ipilimumab vs Sunitinib in Advanced Kidney Cancer
Nizar M. Tannir, MD, of The University of Texas MD Anderson Cancer Center, discusses overall survival and an independent review of response in CheckMate 214 with 42-month fol...
Ziad Bakouny, MD, on Sarcomatoid and Rhabdoid RCC: Potential Determinants of Poor Prognosis and Treatment Response
Ziad Bakouny, MD, of Dana-Farber Cancer Institute, discusses two types of renal cell cancer that are associated with poor prognosis. Because recent early data suggest these t...
Karim Fizazi, MD, PhD, on Prostate Cancer: Pain and Quality of Life in Patients Receiving Cabazitaxel vs Abiraterone or Enzalutamide
Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, discusses results from the CARD study, which showed that cabazitaxel improved pain, time to pain progression, and sympt...
Nicholas D. James, PhD, MBBS, on Adding Abiraterone to Hormone Therapy in Prostate Cancer: STAMPEDE Trial on Cost-Effectiveness
Nicholas D. James, PhD, MBBS, of The Institute of Cancer Research in London, discusses the health economics of adding abiraterone to first-line, long-term hormone therapy in ...
Toni K. Choueiri, MD, on COSMIC-313: Cabozantinib in Combination With Nivolumab/Ipilimumab in RCC
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, describes a currently recruiting phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimu...
